scispace - formally typeset
E

Els Goulmy

Researcher at Leiden University Medical Center

Publications -  193
Citations -  11954

Els Goulmy is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Minor histocompatibility antigen & Cytotoxic T cell. The author has an hindex of 58, co-authored 193 publications receiving 11716 citations. Previous affiliations of Els Goulmy include Leiden University.

Papers
More filters
Journal ArticleDOI

Mismatches of Minor Histocompatibility Antigens between HLA-Identical Donors and Recipients and the Development of Graft-Versus-Host Disease after Bone Marrow Transplantation

TL;DR: A mismatch of minor histocompatibility antigen HA-1 can cause GVHD in adult recipients of allogeneic bone marrow from HLA-identical donors, and ProspectiveHA-1 typing may improve donor selection and identify recipients who are at high risk for GV HD.
Journal ArticleDOI

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.

TL;DR: HA-1- and HA-2-specific cytotoxic T lymphocytes emerging in the blood of patients after DLI demonstrate graft-versus-leukemia or myeloma reactivity resulting in a durable remission, implying that in vitro generated HA- 1- and HLA-A2/HA-2 peptide tetrameric complexes could be used as adoptive immunotherapy to treat hematological malignances relapsing after alloSCT.
Journal ArticleDOI

The minor histocompatibility antigen HA-1 : A diallelic gene with a single amino acid polymorphism

TL;DR: HA-1 allele typing of donor and recipient should improve donor selection and allow the determination of bone marrow transplantation recipients with high risk for HA-1-induced GvHD development.
Journal ArticleDOI

Identification of a Graft-versus-Host Disease-associated human minor Histocompatibility antigen.

TL;DR: A HLA-A2.1-bound peptide representing HA-2 has been identified and appears to originate from a member of the non-filament-forming class I myosin family, which is a candidate for immunotherapeutic intervention in bone marrow transplantation.
Journal ArticleDOI

Human minor Histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy

TL;DR: The results of clinical BMT reveal that the selection of MHC‐identical donors'bone marrow (BM) is no guarantee for avoiding GVHD or ensuring disease‐free survival even when donor and recipient are closely related.